SCHEMBL4817625

SCHEMBL4817625

Brc1ccc2c(c1)CCC21OCCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.40
TDP2 O95551 1/20 0.38
PNMT P11086 2/20 0.37
ASIC3 Q9UHC3 1/20 0.37
PARP10 Q53GL7 2/20 0.34
PARP1 P09874 2/20 0.34
PARP11 Q9NR21 1/20 0.34
APP P05067 1/20 0.33
BACE1 P56817 2/20 0.33
CMA1 P23946 1/20 0.33
AHR P35869 1/20 0.33
PKM P14618 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
METAP1 P53582 1/20 0.32
HSD17B3 P37058 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31660653 0.87 KDM1A (0.49) KDM1ATDP2PNMTASIC3PARP10
SCHEMBL4807456 0.87 KDM1A (0.49) KDM1ATDP2PNMTASIC3PARP10
SCHEMBL22567805 0.81 TDP2 (0.40) KDM1ATDP2PNMTASIC3PARP10
SCHEMBL24478416 0.76 KDM1A (0.41) KDM1ATDP2PNMTASIC3PARP1
SCHEMBL17509598 0.75 ALDH1A1 (0.36) TDP1
SCHEMBL4815280 0.75 ESR2 (0.37)
SCHEMBL22471609 0.74 KDM1A (0.39) KDM1ATDP2PNMTASIC3PARP10
SCHEMBL9049308 0.74 LMNA (0.44) APPBACE1AHRPKMSMN1; SMN2
SCHEMBL6652414 0.74 APP (0.40) KDM1ATDP2PNMTASIC3PARP10
SCHEMBL3990720 0.74 APP (0.40) KDM1ATDP2PNMTASIC3PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
WO-2016025681-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-02-18 WO disclosed
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 KDM1A 2567/4885TDP2 1534/4885PNMT 3845/4885
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF CD4, CD81, ICAM1 KDM1A 1632/4885TDP2 4142/4885PNMT 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.